Dellann Elliott Mydland on Testing Brain Tumor Tissue

Article

Dellann Elliott Mydland, from the Chris Elliott Fund, discusses the importance of testing brain tumor tissue before surgery.

Dellann Elliott Mydland, from the Chris Elliott Fund, discusses the importance of testing brain tumor tissue before surgery.

Recent Videos
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
yellow background with a white outline indicating a brain

Dordaviprone Seeks FDA Approval for Recurrent H3K27M+ Diffuse Glioma

Chris Ryan
January 5th 2025
Article

A new drug application has been submitted to the FDA for dordaviprone to treat recurrent H3K27M-mutant diffuse glioma.

The Vitals

Jacki Garcia and Kristin Hendrickson on Navigating Patients Through Phase 0 Trials

Lindsay Fischer
July 15th 2023
Podcast

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

FDA Approves Ion Torrent Oncomine Dx Target for Brain Cancer

FDA Approves Ion Torrent Oncomine Dx Target for Brain Cancer

Caroline Seymour
October 21st 2024
Article

The FDA approved a companion diagnostic for vorasidenib for patients with grade 2 astrocytoma or oligodendroglioma.

drawing of a brain on yellow background

MTX110 May Improve Survival in Glioblastoma

Russ Conroy
October 21st 2024
Article

An investigational formula of panobinostat called MTX110 may improve outcomes in patients with recurrent glioblastoma.

brain with a tumor in it

MR-Linac Reduced Radiation to Healthy Brain Tissue in Glioma

Russ Conroy
October 12th 2024
Article

Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.

Oncology Drugs Approved by the FDA in August 2024

Oncology Drugs Approved by the FDA in August 2024

Darlene Dobkowski, MA
September 3rd 2024
Article

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.